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Abstract
Purpose Management of the unexplained, painful large diam-
eter metal-on-metal (MOM) hip replacement is difficult.
Although there are guidelines for surgeons, there is no clear
documented evidence describing the overall threshold for
revision surgery. The 2010 product recall of the DePuy
Articular Surface Replacement (ASR) and subsequent media
coverage may have increased patient and surgeon apprehen-
sion, resulting in earlier intervention, i.e. at a greater Oxford
hip score (OHS) than expected. Our aim was to investigate
whether the threshold for revision using known parameters
was affected by the ASR recall. These parameters include
poor clinical results (persistent pain ormechanical symptoms),
pseudotumour or other progressive soft tissue involvement,
osteolysis and high or rising metal ion levels.
Methods We used our national referral database of MOM
hips, which were revised between 2008 and 2012. Once
inclusion and exclusion criteria were applied, we identified
240 patients—71 patients in the pre-recall group and 169
patients in the post-recall group.
Results The ASR product recall did not seem to affect the
threshold for revision of a MOM hip, with no significant
difference between the two groups in terms of the functional
(median OHS = 17 pre-recall and 20 post-recall; p=0.2109)
and radiological (median inclination angle = 50 pre-recall and
48 post-recall; p=0.3221) markers used to guide management.
We did however discover that blood metal ion levels were
higher in the post-recall group.
Conclusion Issue of a product recall did not change the hip
function threshold for revision surgery. The decision to revise
a metal-on-metal hip is complex and should follow published
guidelines, encompassing metal ion measurement and cross-
sectional imaging where appropriate.
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Introduction
The management of the painful large diameter metal-on-metal
(MOM) hip replacement is difficult. In addition to clinical
symptoms and signs, a surgeon will use serological tests and
radiological investigations to assess the risks and benefits of
revision surgery. There are guidelines for surgeons [1] which
suggest considering revision dependent on the patient’s symp-
toms, if there is abnormal imaging and/or rising blood metal
ion levels. However, there is no clear documented evidence
describing the overall threshold for revision surgery.
In all cases, the complete clinical picture should be evalu-
ated before making a decision to revise. In cases with extreme
clinical or investigational parameters the decision is relatively
straightforward. For example, surgeons would consider revi-
sion in cases where: the patient was significantly symptomat-
ic, with anOxford hip score (OHS) less than 30 (out of 48) and
raised blood metal ion levels (>7 ppb) [2, 3]; or if metal
artifact reduction sequence (MARS) MRI revealed a large
(>10 cm) solid pseudotumour or gross soft tissue damage [1,
4]. Conversely, most would consider non-surgical manage-
ment in cases where: the patient was asymptomatic, the OHS
was greater than 41 out 48; blood metal ion levels were
<5 ppb; and MARS MRI revealed no pseudotumour, fluid
or muscle abnormalities.
Management of patients with parameters in the “grey”
(intermediate) zones or those with unexplained pain can be
difficult and psychological factors may also play an important
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role in such cases. The 2010 product recall of the ASR hip [5,
6] and subsequent media coverage suggesting a public health
scare may have increased patient and surgeon apprehension
[7], resulting in a lower threshold for hip revision surgery. Our
aim was to investigate whether the threshold for revision,
using known parameters such as the OHS, was affected by
the ASR recall. We hypothesise that intervention was being
carried out at a higher OHS following the recall (i.e. a lower
threshold).
Materials and methods
We used our national referral database of MOM hips, which
were revised between 2008 and 2012. Data collected included
age, months to revision, head and cup size (in mm), pre-
revision cobalt and chromium levels (in ppb), pre-operative
OHS and radiographic inclination angles.
Inclusion/exclusion criteria
All patients with an OHS undergoing revision of a MOM hip
arthroplasty for unexplained pain were included in the study.
We excluded any patients with an incomplete data set and all
hips that were revised for a known cause (including infection,
fracture, or radiologically confirmed osteolysis and
loosening).
Statistical analysis was performed using the Prism statistics
program (Prism 5.0a, GraphPad Software Inc, La Jolla,
California, USA). The Mann Whitney U-test was used for
non-parametric data; Fisher’s exact test was used for categor-
ical data; and the chi-squared test was used to compare pro-
portions. Level of significance was p<0.05.
Institutional Review Board approval was obtained from the
Riverside Ethics Committee (COREC 07/Q0401/25).
Results
We identified 285 patients between 2008 and 2012 who fulfilled
our inclusion criteria. Of these, 111were pre-recall and 174were
post-recall. Once exclusion criteria were applied, we produced a
final number of 240 patients, of which 71 patients were in the
pre-recall group and 169 patients in the post-recall group.
Patient demographics
Pre-recall group
There were 32 males and 39 females in the pre-recall group
(Table 1).
The following implants were revised: 26 Smith & Nephew
Birmingham hip resurfacings (BHR), 20 Depuy ASR, nine
Zimmer Durom, seven Corin Cormet, three Biomet M2a
Magnum, two Finsbury Adept and one case each of four other
implants. The median OHS was 17 (interquartile range
[IQR] = 10–26), and the median inclination angle was 50
(IQR = 45–55). The median age was 56 (IQR = 48–60) with
a median time to revision of 33 months (IQR = 18–47).
Median head size in this group was 46 mm (IQR = 44–50).
Blood metal ion levels in this group showed a median
chromium of 3.4 ppb (IQR = 1.8–7.4) and a median Cobalt
of 4.2 ppb (IQR = 1.5–11).
Post-recall group
There were 74 males and 95 females in the post-recall group
(Table 2).
The following implants were revised: 42 Smith & Nephew
BHR, 60 Depuy ASR, six Zimmer Durom, 28 Corin Cormet,
two Biomet M2a Magnum, six Finsbury Adept and 25 others.
The median OHS was 20 (IQR = 13–26), and the median
Table 1 Pre-recall group results and statistics
Parameter Age Head size Co Cr OHS Inclination
Minimum 21.00 36.00 0.0 0.1400 2.000 28.00
25 % percentile 48.00 44.00 1.500 1.845 10.00 45.00
Median 56.00 46.00 4.200 3.400 17.00 50.00
75 % percentile 60.00 50.00 10.50 7.383 26.00 55.00
Maximum 82.00 56.00 167.0 119.0 45.00 89.00
Table 2 Post-recall group results and statistics
Parameter Age Head size Co Cr OHS Inclination
Minimum 29.00 28.00 0.2200 0.5300 1.000 33.00
25 % percentile 49.00 44.00 3.000 2.200 13.00 42.00
Median 56.00 47.00 7.350 5.000 20.00 48.00
75 % percentile 62.00 50.00 18.61 13.70 26.00 53.00
Maximum 107.0 56.00 237.0 78.16 48.00 108.0
Graph 1 Comparison of implants revised pre- and post-recall
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inclination angle was 48 (IQR = 42–53). The median age was
56 (IQR = 49–62) with a median time to revision of 50months
(IQR = 36–71). Median head size was 47 mm (IQR = 44–50).
Blood metal ion levels in this group showed a median chro-
mium of 5.0 ppb (IQR = 2.2–14) and a median Cobalt of
7.4 ppb (IQR = 3.0–19).
Group comparisons
Prior to the recall, implants were revised earlier (median
33 months pre-recall compared to 50 months post-recall)
and this was found to be statistically significant (p<0.0001).
There was no significant difference in head sizes (p=0.9778)
or inclination angles (p=0.3221) between the two groups.
Cobalt ion levels were significantly higher in implants revised
post-recall (p=0.01). Chromium ion levels were also higher in
implants revised post-recall, but this was not statistically
significant (p=0.053). The median OHS was 17/48 pre-
recall and 20/48 post-recall. This may suggest a slightly lower
threshold for clinicians to revise, but this was not statistically
significant (p=0.2109).
The mix of implants was found to be significantly different
between the two groups, with p=0.073 (Graph 1). Notably,
there was an increase in the percentage of ASRs being revised
as a total of all implants. Prior to the recall, 20 of the 71
implants revised were the ASR (28 %), whereas following the
recall this rose to 60 out of 169 (35.5 %).
Discussion
In 2010 there was a worldwide withdrawal from the market of
the DePuyASRmetal-on-metal hip replacement system (ASR
hip resurfacing and ASR XLTHR, DePuy, Warsaw, Indiana,
USA) because of higher than expected failure rates [5]. It was,
and has been, the focus of much media attention leaving
patients understandably concerned [8, 9]. One may expect
that, with this fear and dissatisfaction amongst their patients,
surgeons might lower their threshold for intervention in these
cases. Although there have been previous recalls of failing
implantable devices, including other hip prostheses [10, 11]
and breast implants [12], the effect on thresholds for interven-
tion following these recalls have never been examined.
Reviewing our results, some of the findings were to be
expected. For example, following the ASR recall the percent-
age of ASR hips being revised (as a percentage of all hips
revised) increased significantly (p=0.0073). Additionally we
found that there was no difference between the two groups in
terms of implant sizes and positioning—both documented risk
factors for a failing MOM implant [13].
The mean OHS pre-recall was 19 (median = 17),
while post-recall it was 21 (median = 20). This would
suggest that there was a lower threshold to revise post-recall,
i.e. hips were being revised at a higher functional level;
however, this difference was not statistically significant.
It was interesting to discover that both serum cobalt and
chromium ion levels were higher in the post recall group,
although only cobalt ion levels were significantly different.
This would suggest that following the recall, surgeons were
more wary of the risk of failure and more likely to intervene if
metal ion levels were abnormal. It would also suggest that
elevated blood cobalt levels are a matter of concern, particu-
larly in asymptomatic patients. Cobalt levels greater than
10ug/l are thought to greatly increase the risk of osteolysis,
and hence failure of the implant.
Other findings were less predictable. For example, implants
were revised earlier pre-recall (at mean 37.75 months) rather
than post-recall (mean 55.2 months). This was an unexpected
finding and has uncertain clinical relevance. The focus of this
study was on the threshold of revision surgery based on hip
function rather than time to revision. However, there is emerg-
ing evidence to suggest a ‘watchful waiting’ approach for
many patients in ‘grey’ categories (such as asymptomatic
patients with raised metal ions or pseudotumour) [14].
There are limitations to our study. This is a retrospective
study with relatively small cohorts. The decision to proceed
with revision hip surgery in these cases is a complex one.
There are multiple factors to consider and these cannot all be
measured in a standardized way. However recruitment to the
study was identical pre- and post-recall in order to reduce
selection bias. It should be noted that our findings are limited
to the time period we studied (two years either side of the
recall). Decision making may have been affected but not
within the first few years of the recall.
One may expect a product recall to cause the threshold for
intervention to drop and for surgeons to intervene early in any
case where there are doubts over the performance or safety of
an implant. However, from this data it would appear that
MOM hips were actually performing for longer or being
revised later.
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